Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 6, 2015, Pages 6847-6858

  Zou, Jing ^a   Yin, Fuqiang ^a   Wang, Qi ^a   Zhang, Wei ^a   Li, Li ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Bioinformatics; Drug resistance; Expression profiling microarray; Gene; microRNA; Ovarian cancer

Indexed keywords

EPHRIN RECEPTOR A7; LEUKOCYTE ELASTASE INHIBITOR; MICRORNA; TUMOR MARKER;

BIOLOGY; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETICS; HUMAN; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; RECEPTOR, EPHA7;

EID: 84938630518     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Gou Q, Liu L, Wang C, Wu Q, Sun L, Yang X, Xie Y, Li P and Gong C. Polymeric nanoassemblies entrapping curcumin overcome multidrug resistance in ovarian cancer. Colloids Surf B Biointerfaces 2015; 126: 26-34.
3. Yin F, Liu X, Li D, Wang Q, Zhang W and Li L. Tumor suppressor genes associated with drug resistance in ovarian cancer (review). Oncol Rep 2013; 30: 3-10.
4. Davis S and Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 2007; 23: 1846-1847.
5. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA and Brown R. Candidate DNA methylation drivers of acquired cisplatin resistancein ovarian cancer identified by methylome and expression profiling. Oncogene 2012; 31: 4567-4576.
6. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S and Nephew KP. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009; 2: 34.
7. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S and Soboleva A. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res 2013; 41: D991-995.
8. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T and Hatzigeorgiou AG. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 2012; 40: W498-504.
9. Huang da W, Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
10. Chen J, Bardes EE, Aronow BJ and Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 2009; 37: W305-311.
11. Mostafavi S, Ray D, Warde-Farley D, Grouios C and Morris Q. GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol 2008; 9 Suppl 1: S4.
12. John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS. Human MicroRNA targets. PLoS Biol 2004; 2: e363.
13. Griffiths-Jones S, Saini HK, van Dongen S and Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36: D154-158.
14. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
15. Dweep H, Gretz N and Sticht C. miRWalk database for miRNA-target interactions. Methods Mol Biol 2014; 1182: 289-305.
16. Loher P and Rigoutsos I. Interactive exploration of RNA22 microRNA target predictions. Bioinformatics 2012; 28: 3322-3323.
17. Li L, Luan Y, Wang G, Tang B, Li D, Zhang W, Li X, Zhao J, Ding H, Reed E and Li QQ. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med 2004; 14: 257-264.
18. Rao X, Huang X, Zhou Z and Lin X. An improvement of the 2 (-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath 2013; 3: 71-85.
19. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008; 111: 478-486.
20. van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J and Wiemer EA. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013; 32: 4284-4293.
21. Li J, Zhang Y, Gao Y, Cui Y, Liu H, Li M and Tian Y. Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer. Oncol Rep 2014; 32: 979-988.
22. Cheaib B, Auguste A and Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer 2015; 34: 4-16.
23. Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC Jr, Hortobagyi GN and Hung MC. FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Res 2011; 71: 6878-6887.
24. Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, Liu J, Xiao W, Ling B, Wu Q, Song L and Wei W. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer Immunol Immunother 2011; 60: 339-348.
25. Barhoumi R, Bailey HR, Hutchinson RW, Bowen JA and Burghardt RC. Enhancement of melphalan toxicity by octanol in ovarian adenocarcinoma cell lines: effects of altered cell-cell communication, glutathione levels, and plasma membrane fluidity. Fundam Appl Toxicol 1995; 25: 70-79.
26. Al-Bahlani S, Fraser M, Wong AY, Sayan BS, Bergeron R, Melino G and Tsang BK. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene 2011; 30: 4219-4230.
27. Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, Gilmour R, Graff JR, Jambrina E, Mader M, McCann D, Na S, Parsons SH, Pratt SE, Shih C, Stancato LF, Starling JJ, Tate C, Velasco JA, Wang Y and Ye XS. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther 2014; 13: 364-374.
28. Ding L, Kim M, Kanchi KL, Dees ND, Lu C, Griffith M, Fenstermacher D, Sung H, Miller CA, Goetz B, Wendl MC, Griffith O, Cornelius LA, Linette GP, McMichael JF, Sondak VK, Fields RC, Ley TJ, Mule JJ, Wilson PK and Weber JS. Clonal architectures and driver mutations in metastatic melanomas. PLoS One 2014; 9: e111153.
29. Kim JC, Kim SY, Cho DH, Roh SA, Choi EY, Jo YK, Jung SH, Na YS, Kim TW and Kim YS. Genome-wide identification of chemosensitive single nucleotide polymorphism markers in colorectal cancers. Cancer Sci 2010; 101: 1007-1013.
30. X Liu, Y Gao, Y Lu, J Zhang, L Li and F Yin. Oncogenes associated with drug resistance in ovarian cancer. J Cancer Res Clin Oncol 2015; 141: 381-395.
31. Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK. TP53 oncomorphic mutations predict resistance to platinum and taxanebased standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol 2015; 46: 607-618.
32. Lu M, Xiao L, Hu J, Deng S and Xu Y. Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells. J Huazhong Univ Sci Technolog Med Sci 2008; 28: 451-455.
33. Moorehead RA and Singh G. Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 2000; 59: 337-345.
34. Sharifian A, Pourhoseingholi MA, Norouzinia M and Vahedi M. Ovarian cancer in Iranian women, a trend analysis of mortality and incidence. Asian Pac J Cancer Prev 2014; 15: 10787-10790.
35. Sheng WJ, Jiang H, Wu DL and Zheng JH. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer. Braz J Med Biol Res 2013; 46: 650-658.
36. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010; 70: 5184-5193.
37. Kong Y, Bai PS, Sun H, Nan KJ, Chen NZ and Qi XG. The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer. Int J Biochem Cell Biol 2012; 44: 2321-2332.
38. Xu N, Zhang J, Shen C, Luo Y, Xia L, Xue F and Xia Q. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 2012; 423: 826-831.
39. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R and Slaby O. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012; 7: 195.
40. Lis R, Touboul C, Halabi NM, Madduri AS, Querleu D, Mezey J, Malek JA, Suhre K and Rafii A. Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile. J Transl Med 2014; 12: 59.
41. Morales M, Planet E, Arnal-Estape A, Pavlovic M, Tarragona M and Gomis RR. Tumor-stroma interactions a trademark for metastasis. Breast 2011; 20 Suppl 3: S50-55.
42. Meng E, Mitra A, Tripathi K, Finan MA, Scalici J, McClellan S, Madeira da Silva L, Reed E, Shevde LA, Palle K and Rocconi RP. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling. PLoS One 2014; 9: e107142.
43. Amable L, Gavin E, Kudo K, Meng E, Rocconi RP, Shevde LA and Reed E. GLI1 upregulates C-JUN through a specific 130-kDa isoform. Int J Oncol 2014; 44: 655-661.
44. Januchowski R, Zawierucha P, Rucinski M, Nowicki M and Zabe Ml. Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Res Int 2014; 2014: 365867.
45. Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Carrara L, Tassi R, Pecorelli S, Lockwood CJ and Santin AD. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor. Clin Exp Metastasis 2011; 28: 689-700.